{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sun D"],"funding":["National Natural Science Foundation of China"],"pagination":["1527-1535"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6768892"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["68(9)"],"pubmed_abstract":["<h4>Background</h4>Evidence for the efficacy of immunotherapy in biliary tract cancer (BTC) is limited and unsatisfactory.<h4>Methods</h4>Chinese BTC patients receiving a PD-1 inhibitor with chemotherapy, PD-1 inhibitor monotherapy or chemotherapy alone were retrospectively analyzed. The primary outcome was overall survival (OS). The key secondary outcomes were progression-free survival (PFS) and safety. Patients previously treated with any agent targeting T cell costimulation or immune checkpoints were excluded.<h4>Results</h4>The study included 77 patients (a PD-1 inhibitor plus chemotherapy, n = 38; PD-1 inhibitor monotherapy, n = 20; chemotherapy alone, n = 19). The median OS was 14.9 months with a PD-1 inhibitor plus chemotherapy, significantly longer than the 4.1 months with PD-1 inhibitor monotherapy (HR 0.37, 95% CI 0.17-0.80, P = 0.001) and the 6.0 months with chemotherapy alone (HR 0.63, 95% CI 0.42-0.94, P = 0.011). The median PFS was 5.1 months with a PD-1 inhibitor plus chemotherapy, significantly longer than the 2.2 months with PD-1 inhibitor monotherapy (HR 0.59, 95% CI 0.31-1.10, P = 0.014) and the 2.4 months with chemotherapy alone (HR 0.61, 95% CI 0.45-0.83, P = 0.003). Grade 3 or 4 treatment-related adverse events were similar between the anti-PD-1 combination group and the chemotherapy alone group (34.2% and 36.8%, respectively).<h4>Conclusions</h4>Anti-PD-1 therapy plus chemotherapy is an effective and tolerable approach for advanced BTC."],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer."],"pmcid":["PMC6768892"],"funding_grant_id":["81672996","81402552"],"pubmed_authors":["Cui P","Zheng X","Cai S","Hu Y","Zhang J","Chen G","Du W","Wang J","Song J","Gao C","Zhao X","Li X","Wu Z","Qian Y","Sun D","Ma J","Han C","Chen S","Yue Z"],"additional_accession":[]},"is_claimable":false,"name":"Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer.","description":"<h4>Background</h4>Evidence for the efficacy of immunotherapy in biliary tract cancer (BTC) is limited and unsatisfactory.<h4>Methods</h4>Chinese BTC patients receiving a PD-1 inhibitor with chemotherapy, PD-1 inhibitor monotherapy or chemotherapy alone were retrospectively analyzed. The primary outcome was overall survival (OS). The key secondary outcomes were progression-free survival (PFS) and safety. Patients previously treated with any agent targeting T cell costimulation or immune checkpoints were excluded.<h4>Results</h4>The study included 77 patients (a PD-1 inhibitor plus chemotherapy, n = 38; PD-1 inhibitor monotherapy, n = 20; chemotherapy alone, n = 19). The median OS was 14.9 months with a PD-1 inhibitor plus chemotherapy, significantly longer than the 4.1 months with PD-1 inhibitor monotherapy (HR 0.37, 95% CI 0.17-0.80, P = 0.001) and the 6.0 months with chemotherapy alone (HR 0.63, 95% CI 0.42-0.94, P = 0.011). The median PFS was 5.1 months with a PD-1 inhibitor plus chemotherapy, significantly longer than the 2.2 months with PD-1 inhibitor monotherapy (HR 0.59, 95% CI 0.31-1.10, P = 0.014) and the 2.4 months with chemotherapy alone (HR 0.61, 95% CI 0.45-0.83, P = 0.003). Grade 3 or 4 treatment-related adverse events were similar between the anti-PD-1 combination group and the chemotherapy alone group (34.2% and 36.8%, respectively).<h4>Conclusions</h4>Anti-PD-1 therapy plus chemotherapy is an effective and tolerable approach for advanced BTC.","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Sep","modification":"2025-04-21T23:21:10.459Z","creation":"2019-10-30T08:17:34Z"},"accession":"S-EPMC6768892","cross_references":{"pubmed":["31535160"],"doi":["10.1007/s00262-019-02386-w"]}}